Rebecka Hellsten
YOU?
Author Swipe
View article: pSTAT3 Expression is Increased in Advanced Prostate Cancer in Post‐Initiation of Androgen Deprivation Therapy
pSTAT3 Expression is Increased in Advanced Prostate Cancer in Post‐Initiation of Androgen Deprivation Therapy Open
Background The transcription factor Signal Transducer and Activator of Transcription 3 (STAT3) plays a role in carcinogenesis and is involved in processes, such as proliferation, differentiation, drug resistance and immunosuppression. STAT…
View article: Supplementary figure S4 from Therapeutic Targeting of Nuclear γ-Tubulin in RB1-Negative Tumors
Supplementary figure S4 from Therapeutic Targeting of Nuclear γ-Tubulin in RB1-Negative Tumors Open
Supplementary figure S4. The effect of the vehicle, Miglyol Oil 812, in the body weight of treated mice xenografted with U1690 cells.
View article: Supplementary figure S5 from Therapeutic Targeting of Nuclear γ-Tubulin in RB1-Negative Tumors
Supplementary figure S5 from Therapeutic Targeting of Nuclear γ-Tubulin in RB1-Negative Tumors Open
Supplementary figure S5. The effect of CDA on tumor growth of xenografted U1690 cells in the presence or absence of RB1 expression.
View article: Video 4 from Therapeutic Targeting of Nuclear γ-Tubulin in RB1-Negative Tumors
Video 4 from Therapeutic Targeting of Nuclear γ-Tubulin in RB1-Negative Tumors Open
Video 4. Differential Interference Contrast (DIC)/fluorescence time-lapse microscopy images of a mitotic MCF10A cell treated with 100 μM CDA. Hoechst 33258 was used to stain chromatin. Images were collected every 30 s.
View article: Data from Therapeutic Targeting of Nuclear γ-Tubulin in RB1-Negative Tumors
Data from Therapeutic Targeting of Nuclear γ-Tubulin in RB1-Negative Tumors Open
In addition to its cytosolic function, γ-tubulin is a chromatin-associated protein. Reduced levels of nuclear γ-tubulin increase the activity of E2 promoter-binding factors (E2F) and raise the levels of retinoblastoma (RB1) tumor suppresso…
View article: Supplementary material and methods from Therapeutic Targeting of Nuclear γ-Tubulin in RB1-Negative Tumors
Supplementary material and methods from Therapeutic Targeting of Nuclear γ-Tubulin in RB1-Negative Tumors Open
Supplementary material and methods. Contains legends to supplementary Figures and movies and supplementary methods.
View article: Video 2 from Therapeutic Targeting of Nuclear γ-Tubulin in RB1-Negative Tumors
Video 2 from Therapeutic Targeting of Nuclear γ-Tubulin in RB1-Negative Tumors Open
Video 2. Fluorescence images from a time-lapse confocal microscopy using a laser-scanning confocal microscope of a mitotic U2OS cell transiently expressing pmTurquoise2-tagged- α-tubulin (red) treated with 100 μM CDA. Images were col…
View article: Video 2 from Therapeutic Targeting of Nuclear γ-Tubulin in RB1-Negative Tumors
Video 2 from Therapeutic Targeting of Nuclear γ-Tubulin in RB1-Negative Tumors Open
Video 2. Fluorescence images from a time-lapse confocal microscopy using a laser-scanning confocal microscope of a mitotic U2OS cell transiently expressing pmTurquoise2-tagged- α-tubulin (red) treated with 100 μM CDA. Images were col…
View article: Supplementary figure S4 from Therapeutic Targeting of Nuclear γ-Tubulin in RB1-Negative Tumors
Supplementary figure S4 from Therapeutic Targeting of Nuclear γ-Tubulin in RB1-Negative Tumors Open
Supplementary figure S4. The effect of the vehicle, Miglyol Oil 812, in the body weight of treated mice xenografted with U1690 cells.
View article: Video 1 from Therapeutic Targeting of Nuclear γ-Tubulin in RB1-Negative Tumors
Video 1 from Therapeutic Targeting of Nuclear γ-Tubulin in RB1-Negative Tumors Open
Video 1. Fluorescence images from time-lapse confocal microscopy using a laser-scanning confocal microscope of a mitotic U2OS cell transiently expressing pmTurquoise2-tagged- α-tubulin (red) treated with DMSO (vehicle). Images were coll…
View article: Supplementary figure S2 from Therapeutic Targeting of Nuclear γ-Tubulin in RB1-Negative Tumors
Supplementary figure S2 from Therapeutic Targeting of Nuclear γ-Tubulin in RB1-Negative Tumors Open
Supplementary figure S2. The GTPase domain of γ-tubulin. Sequence
View article: Supplementary figure S2 from Therapeutic Targeting of Nuclear γ-Tubulin in RB1-Negative Tumors
Supplementary figure S2 from Therapeutic Targeting of Nuclear γ-Tubulin in RB1-Negative Tumors Open
Supplementary figure S2. The GTPase domain of γ-tubulin. Sequence
View article: Video 3 from Therapeutic Targeting of Nuclear γ-Tubulin in RB1-Negative Tumors
Video 3 from Therapeutic Targeting of Nuclear γ-Tubulin in RB1-Negative Tumors Open
Video 3. Differential Interference Contrast (DIC)/fluorescence time-lapse microscopy images of a mitotic MCF10A treated with DMSO (vehicle). Hoechst 33258 was used to stain chromatin. Images were collected every 30 s.
View article: Supplementary figure S3 from Therapeutic Targeting of Nuclear γ-Tubulin in RB1-Negative Tumors
Supplementary figure S3 from Therapeutic Targeting of Nuclear γ-Tubulin in RB1-Negative Tumors Open
Supplementary figure S3. Dimethyl fumarate interacts with the GTP/GDP binding pocket of γ-tubulin.
View article: Supplementary figure S6 from Therapeutic Targeting of Nuclear γ-Tubulin in RB1-Negative Tumors
Supplementary figure S6 from Therapeutic Targeting of Nuclear γ-Tubulin in RB1-Negative Tumors Open
Supplementary figure S6. The body weight changes of treated mice xenografted with U1690RB1 cells.
View article: Supplementary figure S1 from Therapeutic Targeting of Nuclear γ-Tubulin in RB1-Negative Tumors
Supplementary figure S1 from Therapeutic Targeting of Nuclear γ-Tubulin in RB1-Negative Tumors Open
Supplementary figure S1. CDA treatment induces a G2/M cell cycle arrest.
View article: Supplementary figure S6 from Therapeutic Targeting of Nuclear γ-Tubulin in RB1-Negative Tumors
Supplementary figure S6 from Therapeutic Targeting of Nuclear γ-Tubulin in RB1-Negative Tumors Open
Supplementary figure S6. The body weight changes of treated mice xenografted with U1690RB1 cells.
View article: Supplementary figure S5 from Therapeutic Targeting of Nuclear γ-Tubulin in RB1-Negative Tumors
Supplementary figure S5 from Therapeutic Targeting of Nuclear γ-Tubulin in RB1-Negative Tumors Open
Supplementary figure S5. The effect of CDA on tumor growth of xenografted U1690 cells in the presence or absence of RB1 expression.
View article: Supplementary material and methods from Therapeutic Targeting of Nuclear γ-Tubulin in RB1-Negative Tumors
Supplementary material and methods from Therapeutic Targeting of Nuclear γ-Tubulin in RB1-Negative Tumors Open
Supplementary material and methods. Contains legends to supplementary Figures and movies and supplementary methods.
View article: Video 4 from Therapeutic Targeting of Nuclear γ-Tubulin in RB1-Negative Tumors
Video 4 from Therapeutic Targeting of Nuclear γ-Tubulin in RB1-Negative Tumors Open
Video 4. Differential Interference Contrast (DIC)/fluorescence time-lapse microscopy images of a mitotic MCF10A cell treated with 100 μM CDA. Hoechst 33258 was used to stain chromatin. Images were collected every 30 s.
View article: Video 3 from Therapeutic Targeting of Nuclear γ-Tubulin in RB1-Negative Tumors
Video 3 from Therapeutic Targeting of Nuclear γ-Tubulin in RB1-Negative Tumors Open
Video 3. Differential Interference Contrast (DIC)/fluorescence time-lapse microscopy images of a mitotic MCF10A treated with DMSO (vehicle). Hoechst 33258 was used to stain chromatin. Images were collected every 30 s.
View article: Video 1 from Therapeutic Targeting of Nuclear γ-Tubulin in RB1-Negative Tumors
Video 1 from Therapeutic Targeting of Nuclear γ-Tubulin in RB1-Negative Tumors Open
Video 1. Fluorescence images from time-lapse confocal microscopy using a laser-scanning confocal microscope of a mitotic U2OS cell transiently expressing pmTurquoise2-tagged- α-tubulin (red) treated with DMSO (vehicle). Images were coll…
View article: Nuclear expression of pSTAT3Tyr705 and pSTAT3Ser727 in the stromal compartment of localized hormone-naïve prostate cancer
Nuclear expression of pSTAT3Tyr705 and pSTAT3Ser727 in the stromal compartment of localized hormone-naïve prostate cancer Open
Nuclear expression of pSTAT3Tyr705 and pSTAT3Ser727 in the stromal cells mirrors previous findings in the epithelial component in that it displays prognostic value in men undergoing radical prostatectomy for localized hormone-naïve PCa.
View article: Inhibition of STAT3 augments antitumor efficacy of anti-CTLA-4 treatment against prostate cancer
Inhibition of STAT3 augments antitumor efficacy of anti-CTLA-4 treatment against prostate cancer Open
There is an urgent need for new treatment options in metastatic drug-resistant prostate cancer. Combining immunotherapy with other targeted therapies may be an effective strategy for advanced prostate cancer. In the present study, we sough…
View article: Cytokines and Janus kinase/signal transducer and activator of transcription signaling in prostate cancer: overview and therapeutic opportunities
Cytokines and Janus kinase/signal transducer and activator of transcription signaling in prostate cancer: overview and therapeutic opportunities Open
The Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway was originally identified as a key cellular mechanism mediating the action of cytokines, interferons, and growth factors for the control of gene express…